Chongqing Zhifei Biological Products News

Zhifei Biotech (300122): 24Q3 performance under pressure awaiting vaccine release

Guotou SecuritiesNov 1, 2024 07:27

Zhifei Biotech (300122): 24Q3 product sales continue to advance under short-term pressure self-development pipeline

cscOct 28, 2024 16:02

Zhifei Biotech (300122): Short performance, sales of shingles vaccine continue to advance under pressure

海通證券Sep 12, 2024 20:16

Zhifei Biology (300122): The HPV vaccine is sold under pressure and the herpes vaccine is expected to be gradually released

Sep 5, 2024 14:36

Zhifei Biotech (300122): Actively strengthening sales capacity building and anticipating a month-on-month improvement in product sales

Sep 3, 2024 18:31

Zhifei Biotech (300122): Exploring the inflection point of Zhifei Biotech's business with three questions and three answers

Jul 11, 2024 19:16

Zhifei Biotech (300122): Exploring the inflection point of Zhifei Biotech's business with three questions and three answers

Jun 26, 2024 00:00

Research Nuggets丨Tianfeng Securities: Maintaining Zhifei Biotech's “Buy” Rating and Sales of Recombinant Herpes Vaccine Is Worth Looking Forward to

Gelonghui FinanceMay 23, 2024 15:52

Zhifei Biotech (300122): Steady growth in recombinant shingles vaccine sales in 2023 is worth looking forward to

May 22, 2024 18:26

Research Report Nuggets丨CITIC Construction Investment: Zhifei Biotech's shingles vaccine contributed new volume and maintained a “buy” rating

Gelonghui FinanceMay 9, 2024 15:49

Zhifei Biotech (300122): The existing business is steady and far reaching new contributions to the shingles vaccine

May 9, 2024 11:26

Zhifei Biotech (300122): HPV vaccine enters steady growth period, focus on shingles vaccine dosage

May 8, 2024 08:11

Zhifei Biotech (300122): Performance during the reporting period was slightly lower than expected, “Self-developed & Agency” dual-drive built a long-term growth engine for performance

Apr 30, 2024 13:26

Zhifei Biotech (300122): Nine valent HPV accelerates the release of shingles and opens up room for growth

Apr 30, 2024 00:00

Zhifei Biotech (300122): HPV vaccine continuous release development pipeline enters harvest period

Apr 29, 2024 18:46

Zhifei Biotech (300122): Further release of the HPV vaccine, and the shingles vaccine will soon contribute new doses

Apr 28, 2024 20:51

Zhifei Biotech (300122): Changes in agent product structure expected to release shingles vaccine

Apr 27, 2024 00:00

Zhifei Biotech (300122) Annual Report Review Report: Company fundamentals, high quality growth, high certainty, and shingles are expected to create a second growth curve

Apr 25, 2024 00:00

Zhifei Biotech (300122) Company Comment: Proposed repurchase of 300 to 500 million yuan of company shares shows confidence in long-term development

Feb 23, 2024 16:26

Zhifei Biotech (300122): “Double Improvement of Quality and Return” Program Boosts Confidence in Stable Development

Feb 19, 2024 18:26